Nicox and Bausch + Lomb have agreed to new financial terms for Vyzulta, which includes an additional $20 million in potential milestone payments, according to a press release.
The original global licensing agreement between the companies included Nicox receiving 10% to 15% of royalties on worldwide net sales of Vyzulta (latanoprostene bunod ophthalmic solution 0.024%), with three tiers triggered by increasing, predefined annual sales levels, the release said.
Under the terms of the new agreement, Bausch + Lomb will pay Nicox an additional 1% over the original royalty on net sales more than $300
Uncategorized